Practical Neurology

06/19/2026

Treatment with was associated with greater reductions in monthly frequency than placebo in the phase 3 X-TOLE2 trial.
https://ow.ly/V57V50ZeJRX
American Academy of Neurology (AAN) Xenon Pharmaceuticals pvt.ltd

KEY TAKEAWAYS Treatment with azetukalner was associated with greater reductions in monthly seizure frequency than placebo in the phase 3 X-TOLE2 trial…

06/19/2026

How should clinicians approach treatment selection in advanced ? Drs. Pinky Agarwal and John B. Sanderson (UW Medicine) discuss current device-aided and infusion therapies, highlighting factors that influence treatment choice, patient selection, and long-term management.

Read more: https://ow.ly/C0Mn50Zczas

International Parkinson and Movement Disorder Society American Academy of Neurology (AAN) AbbVie

Advanced Parkinson Disease Treatment

06/19/2026

Treatment with (Lundbeck US) was associated with reduced monthly days compared with placebo in the intravenous portion of the phase 2b clinical trial. Data presented at 2026
https://ow.ly/J4Se50Zcz90
American Headache Society® American Academy of Neurology (AAN)

KEY TAKEAWAYS The intravenous portion of the phase 2b PROCEED trial met its primary efficacy end point, with bocunebart associated with a statistically …

06/18/2026

Analyzing self-reported diaries provides practical lessons—with implications for outpatient care, clinical trials, & seizure risk forecasting.

Read a review from Dr. Daniel M. Goldenholz on what seizure diaries can teach us about management and research.
https://ow.ly/weiI50Zcz7X
Beth Israel Deaconess Medical Center American Epilepsy Society

06/17/2026

How can health systems scale early detection while making the best use of clinical resources?

🎧 In an episode of Disease Deep Dive, Elyse Perweiler, RN, MPP and Tim MacLeod, PhD, discuss real-world lessons from implementing the Alzheimer’s Collaborative Healthcare System Preparedness US Early Detection Program at Rowan-Virtua School of Osteopathic Medicine.

Listen now: https://ow.ly/TtPm50ZcNUN

Davos Alzheimer's Collaborative Alzheimer's Association American Academy of Neurology (AAN)

This episode explores the real-world implementation of the Davos Alzheimer’s Collaborative Healthcare System Preparedness (DAC-SP) US Early Detection Prog…

06/17/2026

Can cell therapy address the compartmentalized that drives progressive ?

Drs. Sarah Conway & Kristin Galetta explore the rationale, early clinical data, and therapeutic potential of CAR T-cell approaches targeting pathogenic B cells and plasma cells in progressive .
https://ow.ly/3Gg850Zcz6Z
Stanford Medicine Harvard Medical School

06/17/2026

Qulipta ( ) maintained a favorable safety profile and sustained efficacy through 156 weeks in people with chronic or episodic , according to final phase 3 extension study results presented at 2026.

https://ow.ly/fZ8Q50ZaGWf

American Headache Society® American Academy of Neurology (AAN) AbbVie

KEY TAKEAWAYS Qulipta (atogepant) was generally safe and well tolerated through 156 weeks in people with chronic or episodic migraine. No new safety s…

06/14/2026

The cover art for our April issue was created by Amy Bekier, Vice Chair of the FSHD Society. Living with disease, Amy has adapted by teaching herself to paint with her nondominant hand since losing dexterity in the other.
https://ow.ly/E7b550Zb91i

06/13/2026

Progressive & in midlife should raise suspicion for more than normal .

A review by Drs. Minna Choi & Elina Zakin examines the clinical features, genetics, diagnostic workup, & management of muscular ( ), a rare and often underrecognized -related .

https://ow.ly/qOFJ50ZbsFE

American Association of Neuromuscular & Electrodiagnostic Medicine - AANEM American Academy of Neurology (AAN) NYU Langone Health

oculopharyngeal muscular dystrophy

06/12/2026

New from 2026: A network meta-analysis found (Axsome) was associated with greater odds of 2-hour pain freedom, sustained pain freedom, and lower rescue medication use compared with comparator for acute treatment.

https://ow.ly/7v3o50ZaH48

American Headache Society® American Academy of Neurology (AAN)

KEY TAKEAWAYS Symbravo was associated with higher odds of 2-hour pain freedom and 2- to 24-hour sustained pain freedom compared with rimegepant, ubrog…